Skip to main content
2024 Canadian Cardiovascular Congress Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Handout
Handout
Networking
Networking
On-Demand
On-Demand
Early Career Involvement
Early Career Involvement
Back
Session Evaluation

IMAGING

HEART FAILURE

ARTIFICIAL INTELLIGENCE

EARLY CAREER INVOLVEMENT

325 - IMAGING THE THICK HEART: A MULTIMODALITY APPROACH

Saturday, October 26, 2024
9:45 AM – 10:45 AM PT
Room: 212-213
Early Career Involvement
Workshop Description: Echocardiography is a key imaging modality for diagnosis, management, and monitoring of various cardiomyopathies. Increased ventricular wall thickness is often the first clue to amyloid cardiomyopathy, Fabry cardiomyopathy, and hypertrophic cardiomyopathy. There are both overlapping and unique features of these entities. As there are now effective treatments for all these conditions, it is critical that cardiac health providers be familiar with not only the clinical presentation, but also the imaging findings to enhance timely diagnosis and management. The role of multimodality imaging will be discussed. Invited speakers will describe how echocardiography, cardiac MRI, and other imaging modalities are used for diagnosis, management, and monitoring of thick heart conditions. This session will feature a multidisciplinary panel with clinical and/or research experience in hypertrophic cardiomyopathy, amyloidosis, Fabry disease, and mimics of these. The panel will include members from the Canadian Society of Echocardiography, Canadian Heart Failure Society, Canadian Adult Congenital Heart Network, and Canadian Society of MRI. The session will include the following topics:
1. Discuss echo approach to increased left ventricular wall thickness:
A. Echo features of Hypertrophic Cardiomyopathy
B. Echo features Fabry Cardiomyopathy
C. Echo features of Cardiac Amyloidosis
2. Role of cardiac magnetic resonance and other imaging modalities for thick heart assessment
3. Artificial Intelligence solutions for differentiating various cardiomyopathies: are we there yet?
Invited speakers have expertise across these domains. In the first session, there will be 3 sections: participants will learn how to approach a patient with increased wall thickness and recognize the echo features of hypertrophic cardiomyopathy, Fabry cardiomyopathy, and cardiac amyloidosis. The second session will highlight CMR and other imaging modalities for assessment of thick hearts and how these could complement echocardiography in the differentiation of various cardiomyopathies. In the last session, we will discuss artificial intelligence solutions for earlier diagnosis of these cardiomyopathies.

Interactive and Engagement Activities Description: Each speaker will provide an approximate 7-10 minute presentation on the topic assigned. There will be an allotted 10-20 minute discussion period at the end of the session.

Learning Objectives:

At the end of this session participants will be able to:
  • discuss the approach to an increased ventricular thickness on echocardiogram, and learn to recognize features of hypertrophic cardiomyopathy, Fabry disease, and cardiac amyloidosis;
  • participants will learn the role of CMR and other imaging modalities complementary to echocardiography for assessment of thick hearts; and
  • participants will learn about artificial intelligence solutions for automating LV wall thickness and geometry assessment and how these can facilitate earlier diagnosis of various cardiomyopathies.
Disclosure(s):
Sharon L. Mulvagh, MD, FRCPC, FACC, FASE, FAHA: Novo Nordisk: Steering Committee for SOUL Clinical Trial (Ongoing)
Teresa S.M Tsang, MD, FRCPC, FACC, FASE: Bayer: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); Boehringer-Ingelheim: Speaker/Honoraria (Ongoing); Bristol Myers Squibb: Speaker/Honoraria (Ongoing); Pfizer: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Philips: Consultant/Advisory Board (Ongoing); Sanofi: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); Servier: Speaker/Honoraria (Ongoing); Takeda: Speaker/Honoraria (Ongoing)
Nowell M. Fine, MD, FRCPC: No financial relationships to disclose
Wendy Tsang, MD, FRCPC: Abbott: Honoraria (Terminated, December 31, 2023); Philips: Research support (Ongoing); Siemens: Research equipment (Ongoing); UpToDate: Honoraria (Ongoing)
Darwin F. Yeung, MD, FRCPC: Amicus: Speaker/Honoraria (Terminated); Bristol-Myers-Squibb: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); Pfizer: Speaker/Honoraria (Terminated); Sanofi: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); Takeda: Consultant/Advisory Board (Terminated)
Jeff Yim, MD: No financial relationships to disclose
Robin A. Ducas, MD, FRCPC: No financial relationships to disclose
Christina Luong, MD, MHSc, FRCPC, FASE: No financial relationships to disclose